Open original FDA record ↗Recall record
- FDA identifier
- Z-2644-2024
- Company in FDA record
- Ventana Medical Systems, Inc.
- FDA classification date
- Aug 16, 2024
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Their is a potential for high background and off-target staining when using the monoclonal primary antibody which can result in false positive results.
Source facts
- Action
- On July 5, 2024, Ventana Medical Systems, Inc. a subsidiary of Roche Diagnostics issued a "Urgent Medical Device Correction" via UPS to affected consignees. Ventana asked consignees to take the following actions: 1. Discontinue use and discard any remaining affected product in your inventory according to your local waste guidelines. 2. Please consult with the physician or pathologist at your facility to determine specific clinical implications for your patients. 3. Review all positive results generated with the affected lots. Follow your standard laboratory operating procedures to investigate any suspected false positive results generated with the affected lots. 4. If you performed your initial validation using an affected lot, you should revalidate. 5. Refer to the Product Replacement or Credit section on page three of this UMDC. To receive replacement product OR credit for the unexpired product currently in your inventory, use the following link to access the form: https://go.roche.com/TP-02194. 6. Complete all sections of the enclosed Recall Response form (TP-02195); fax or email it according to the instructions on the form even if you are not requesting replacement product or credit. " Share this notification with all device users within your facility and network to ensure they are aware of this recall. This recall notice should also be shared with any organization where the potentially affected devices have been transferred. " File this Urgent Medical Device Correction (UMDC) for future reference.
- Initiated
- 2024-06-27
- Root cause
- Unknown/Undetermined by firm
- Distribution
- Worldwide - US Nationwide distribution including in the states of AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV and the countries of Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Romania, Slovakia, Spain, Sweden, Switzerland, Albania, Argentina, Armenia, Australia, Azerbaijan, Bahrain, Belarus, Brazil, Cameroon, Chile, China, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, Egypt, El Salvador, Georgia, Ghana, Guatemala, Honduras, Hong Kong, India, Iran, Iraq, Israel, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Lebanon, Malaysia, Mali, Mauritania, Mauritius, Mexico, Moldova, Mongolia, Morocco, Myanmar, Nepal, New Zealand, Nicaragua, Nigeria, North Macedonia, Oman, Pakistan, Palestine, Panama, Paraguay, Peru, Philippines, Russian Fed., Rwanda, Saudi Arabia, Serbia, Singapore, South Africa, South Korea, Sri Lanka, Taiwan, Tanzania, Thailand, T¿rkiye, Uganda, United Arab Emirates, United Kingdom, Uruguay, and Vietnam.
- Recall number
- Z-2644-2024
- Recall status
- Open, Classified
- CDRH record ID
- 209033
- FDA classified
- 2024-08-16
- Recall event number
- 94985